Press Release BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer Aug 7
Press Release BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models Jul 28
Press Release BioInvent’s BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026 Jul 17